Abstract
The development of therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of cancer along the last ten years. The best examples of their therapeutic efficacies have been obtained with rituximab for the treatment of CD20+ B-cell Non-Hodgkin Lymphoma (B-NHL), and several others antibodies with optimized bioactivities are now being developed for the treatment of various malignant hemopathies. We review here the main drugs developed in this field, and present some emerging concepts able to improve the bioactivities of the next generation of therapeutic mAbs.
Keywords: Cancer, lymphoma, therapy, antibodies, phosphoantigens
Current Drug Targets
Title: Emerging Concepts for the Treatment of Hematological Malignancies with Therapeutic Monoclonal Antibodies
Volume: 11 Issue: 7
Author(s): Aude-Helene Capietto, Samarh Keirallah, Emilie Gross, Nicolas Dauguet, Emilie Laprevotte, Christine Jean, Julie Gertner-Dardenne, Christine Bezombes, Anne Quillet-Mary, Mary Poupot, Loic Ysebaert, Guy Laurent and Jean-Jacques Fournie
Affiliation:
Keywords: Cancer, lymphoma, therapy, antibodies, phosphoantigens
Abstract: The development of therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of cancer along the last ten years. The best examples of their therapeutic efficacies have been obtained with rituximab for the treatment of CD20+ B-cell Non-Hodgkin Lymphoma (B-NHL), and several others antibodies with optimized bioactivities are now being developed for the treatment of various malignant hemopathies. We review here the main drugs developed in this field, and present some emerging concepts able to improve the bioactivities of the next generation of therapeutic mAbs.
Export Options
About this article
Cite this article as:
Capietto Aude-Helene, Keirallah Samarh, Gross Emilie, Dauguet Nicolas, Laprevotte Emilie, Jean Christine, Gertner-Dardenne Julie, Bezombes Christine, Quillet-Mary Anne, Poupot Mary, Ysebaert Loic, Laurent Guy and Fournie Jean-Jacques, Emerging Concepts for the Treatment of Hematological Malignancies with Therapeutic Monoclonal Antibodies, Current Drug Targets 2010; 11 (7) . https://dx.doi.org/10.2174/138945010791320845
DOI https://dx.doi.org/10.2174/138945010791320845 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Selection and Characterization of Human Anti-MAGE-A1 scFv and Immunotoxin
Anti-Cancer Agents in Medicinal Chemistry Editorial(Hot Topic:Targeting the Ubiquitin-Proteasome Pathway - Current Perspectives and Future Directions)
Current Pharmaceutical Design Roles of miRNA in the Initiation and Development of Colorectal Carcinoma
Current Pharmaceutical Design Copper Chelation Chemistry and its Role in Copper Radiopharmaceuticals
Current Pharmaceutical Design Evaluation of Drug Targeting Strategies and Liposomal Trafficking
Current Pharmaceutical Design Inhibition of Cyclin-Dependent Kinases - A Review of the Recent Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Gemcitabine: A Critical Nucleoside for Cancer Therapy
Current Medicinal Chemistry Aflibercept: A Novel VEGF Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Tumors
Mini-Reviews in Medicinal Chemistry Microscopies at the Nanoscale for Nano-Scale Drug Delivery Systems
Current Drug Targets Pembrolizumab-Induced Seronegative Arthritis and Fasciitis in a Patient with Lung Adenocarcinoma
Current Drug Safety Epigenetic Targets and their Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry A Review on PARP1 Inhibitors: Pharmacophore Modeling, Virtual and Biological Screening Studies to Identify Novel PARP1 Inhibitors
Current Topics in Medicinal Chemistry Poly(ADP-Ribose) Polymerases in Aging – Friend or Foe?
Current Protein & Peptide Science Potential Novel Targets in Breast Cancer
Current Pharmaceutical Biotechnology Advancements in Adjuvanticity of Bioactive Inorganic and Organic Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Stem Cell Transplantation and MBL Replacement Therapy
Current Stem Cell Research & Therapy Antineoplastic Activity of an Old Natural Antidiabetic Biguanide on the Human Thyroid Carcinoma Cell Line
Anti-Cancer Agents in Medicinal Chemistry A Review on the Synthetic Approach of Marinopyrroles: A Natural Antitumor Agent from the Ocean
Letters in Organic Chemistry Safety Profile of Plasmid/Liposomes and Virus Vectors in Clinical Gene Therapy
Current Drug Safety Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry